SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company, announced an update to the design of the ongoing phase 3 ACTIV-2 trial evaluating the clinical efficacy and safety of SAB-185 for the treatment of participants with mild-moderate Covid infections at higher risk for progression to hospitalization.
The phase 3 trial had been designed as an open-label, randomized non-inferiority study comparing SAB-185 to an active comparator
